SAN DIEGO – December 6, 2017 – ResMed has been named a 2017 “Medtech Company of the Year” finalist by MD+DI, a leading news resource in the medical device and diagnostic industry.
“ResMed has made strides this year in encouraging patient adherence with treatment and easing their ability to track progress,” MD+DI stated in an announcement, citing ResMed’s milestone of capturing one billion nights of monitored sleep apnea therapy and a CHEST-published study showing ResMed’s self-monitoring app myAir can help boost therapy adherence to 87 percent.
“ResMed has made strides to improve comfort, too,” MD+DI said, touting the company’s newly launched AirTouch F20 full face mask with memory foam cushion and AirMini, the world’s smallest positive airway pressure (PAP) device.
Also in 2017, ResMed formed the joint venture SleepScore Labs with television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors L.P. to help people understand and improve their sleep.
The company earned $2.1 billion in fiscal year 2017, and in July was named to the S&P 500, Standard & Poor’s list of the 500 largest U.S.-traded companies.
MD+DI will announce its “Medtech Company of the Year” on Monday, December 11. See ResMed and the other finalists here.
ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 4 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com | Facebook | Twitter | LinkedIn
# # #